Relay Therapeutics reports RLY-2608+fulvestrant median PFS 11.4 months in 2L breast cancer; plans pivotal study in 2025

Relay Therapeutics, Inc.

Median PFS 9.2 months overall, 11.4 months in 2L patients at RP2D (600mg BID) without PTEN/AKT co-mutations.
Confirmed ORR 39% overall, 67% in kinase-mutation patients; CBR 67%; median follow-up 9.5 months.
Low discontinuation rate (2 patients due to TRAEs); 94% median dose intensity; only 3% Grade 3 hyperglycemia.
Cash and investments ~$840M as of Q3 2024; funds 2L pivotal study planned for 2025.
Triplet combinations with ribociclib (ongoing) and atirmociclib (initiated) progressing; VMs study in Q1 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.